Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

Draft guidance

Equality impact assessment (downloadable version) (PDF 120 KB)

Draft consultation document (online commenting)

Draft consultation document (downloadable version) (PDF 260 KB)

Public committee slides (PDF 889 KB)

Final stakeholder list (PDF 120 KB)

Final scope (PDF 149 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 163 KB)

Draft matrix post referral (PDF 123 KB)

Note

Note